Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 54Lung Neoplasms 46Neoplasm Metastasis 36Carcinoma, Non-Small-Cell Lung 36Multiple Myeloma 26Breast Neoplasms 26Glioma 23Carcinoma, Renal Cell 22Pancreatic Neoplasms 21Melanoma 21Glioblastoma 21Lymphoma, Large B-Cell, Diffuse 20Squamous Cell Carcinoma of Head and Neck 19Ovarian Neoplasms 19Urinary Bladder Neoplasms 18Lymphoma 18Colorectal Neoplasms 18Triple Negative Breast Neoplasms 15Oropharyngeal Neoplasms 15Mouth Neoplasms 15Brain Neoplasms 15Fallopian Tube Neoplasms 13Carcinoma, Hepatocellular 13Carcinoma 13Laryngeal Neoplasms 12Astrocytoma 12Lymphoma, Follicular 11Leukemia, Myeloid, Acute 11Sarcoma 10Neuroblastoma 10

Interventions

Specimen Handling 1Rituximab 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Classic Follicular Lymphoma × Magnetic Resonance Spectroscopy × 90 days × Clear all
NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡